EKOS Therapy

One-year results from the OPTALYSE PE trial confirm that bilateral pulmonary embolism (PE) patients treated in as little as two hours with a total tissue plasminogen activator (tPA) dose as low as 8mg continue to show improvements in RV/LV ratio over the long term with a very low all-cause mortality rate of 2%.

BTG has announced the commencement of the KNOCOUT PE study, which will measure how hospitals and patients are benefitting from a new standard of care in the treatment of pulmonary embolism (PE) utilising EKOS therapy with faster, and even safer protocols, proven effective in the OPTALYSE PE study. The OPTALYSE PE study found PE can be treated effectively with EKOS therapy over a much shorter period and at safer thrombolytic doses far below the previous standard.

The results of the ACCESS PTS (Accelerated Thrombolysis for Post-Thrombotic Syndrome Using the Ekos System) trial has reported chronic deep vein thrombosis (DVT) patients with post-thrombotic syndrome (PTS) can be treated safely and effectively with EKOS therapy. According to BTG, the ACCESS PTS protocol using EKOS therapy is now the only treatment regimen proven to significantly reduce the signs and symptoms of PTS and show a significant improvement in quality of life. The outcomes were presented at the Society for Vascular Medicine 28th Annual Scientific Sessions in New Orleans.